Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. 1998

S S Frankel, and R M Steinman, and N L Michael, and S R Kim, and N Bhardwaj, and M Pope, and M K Louder, and P K Ehrenberg, and P W Parren, and D R Burton, and H Katinger, and T C VanCott, and M L Robb, and D L Birx, and J R Mascola
Division of Retrovirology, Walter Reed Army Institute of Research and Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, Maryland, USA. sfrankel@hiv.hjf.org

Prevention of the initial infection of mucosal dendritic cells (DC) and interruption of the subsequent transmission of HIV-1 from DC to T cells are likely to be important attributes of an effective human immunodeficiency virus type 1 (HIV-1) vaccine. While anti-HIV-1 neutralizing antibodies have been difficult to elicit by immunization, there are several human monoclonal antibodies (MAbs) that effectively neutralize virus infection of activated T cells. We investigated the ability of three well-characterized neutralizing MAbs (IgG1b12, 2F5, and 2G12) to block HIV-1 infection of human DC. DC were generated from CD14(+) blood cells or obtained from cadaveric human skin. The MAbs prevented viral entry into purified DC and the ensuing productive infection in DC/T-cell cultures. When DC were first pulsed with HIV-1, MAbs blocked the subsequent transmission to unstimulated CD3(+) T cells. Thus, neutralizing antibodies can block HIV-1 infection of DC and the cell-to-cell transmission of virus from infected DC to T cells. These data suggest that neutralizing antibodies could interrupt the initial events associated with mucosal transmission and regional spread of HIV-1.

UI MeSH Term Description Entries
D009092 Mucous Membrane An EPITHELIUM with MUCUS-secreting cells, such as GOBLET CELLS. It forms the lining of many body cavities, such as the DIGESTIVE TRACT, the RESPIRATORY TRACT, and the reproductive tract. Mucosa, rich in blood and lymph vessels, comprises an inner epithelium, a middle layer (lamina propria) of loose CONNECTIVE TISSUE, and an outer layer (muscularis mucosae) of SMOOTH MUSCLE CELLS that separates the mucosa from submucosa. Lamina Propria,Mucosa,Mucosal Tissue,Muscularis Mucosae,Mucous Membranes,Membrane, Mucous,Membranes, Mucous,Mucosae, Muscularis,Mucosal Tissues,Propria, Lamina,Tissue, Mucosal,Tissues, Mucosal
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D003713 Dendritic Cells Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION). Dendritic Cells, Interdigitating,Interdigitating Cells,Plasmacytoid Dendritic Cells,Veiled Cells,Dendritic Cells, Interstitial,Dendritic Cells, Plasmacytoid,Interdigitating Dendritic Cells,Interstitial Dendritic Cells,Cell, Dendritic,Cell, Interdigitating,Cell, Interdigitating Dendritic,Cell, Interstitial Dendritic,Cell, Plasmacytoid Dendritic,Cell, Veiled,Cells, Dendritic,Cells, Interdigitating,Cells, Interdigitating Dendritic,Cells, Interstitial Dendritic,Cells, Plasmacytoid Dendritic,Cells, Veiled,Dendritic Cell,Dendritic Cell, Interdigitating,Dendritic Cell, Interstitial,Dendritic Cell, Plasmacytoid,Interdigitating Cell,Interdigitating Dendritic Cell,Interstitial Dendritic Cell,Plasmacytoid Dendritic Cell,Veiled Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

S S Frankel, and R M Steinman, and N L Michael, and S R Kim, and N Bhardwaj, and M Pope, and M K Louder, and P K Ehrenberg, and P W Parren, and D R Burton, and H Katinger, and T C VanCott, and M L Robb, and D L Birx, and J R Mascola
November 2004, Journal of virology,
S S Frankel, and R M Steinman, and N L Michael, and S R Kim, and N Bhardwaj, and M Pope, and M K Louder, and P K Ehrenberg, and P W Parren, and D R Burton, and H Katinger, and T C VanCott, and M L Robb, and D L Birx, and J R Mascola
February 2011, Virologie (Montrouge, France),
S S Frankel, and R M Steinman, and N L Michael, and S R Kim, and N Bhardwaj, and M Pope, and M K Louder, and P K Ehrenberg, and P W Parren, and D R Burton, and H Katinger, and T C VanCott, and M L Robb, and D L Birx, and J R Mascola
November 1993, Journal of virology,
S S Frankel, and R M Steinman, and N L Michael, and S R Kim, and N Bhardwaj, and M Pope, and M K Louder, and P K Ehrenberg, and P W Parren, and D R Burton, and H Katinger, and T C VanCott, and M L Robb, and D L Birx, and J R Mascola
June 1995, Journal of virology,
S S Frankel, and R M Steinman, and N L Michael, and S R Kim, and N Bhardwaj, and M Pope, and M K Louder, and P K Ehrenberg, and P W Parren, and D R Burton, and H Katinger, and T C VanCott, and M L Robb, and D L Birx, and J R Mascola
January 2008, Virology,
S S Frankel, and R M Steinman, and N L Michael, and S R Kim, and N Bhardwaj, and M Pope, and M K Louder, and P K Ehrenberg, and P W Parren, and D R Burton, and H Katinger, and T C VanCott, and M L Robb, and D L Birx, and J R Mascola
April 2004, Journal of virology,
S S Frankel, and R M Steinman, and N L Michael, and S R Kim, and N Bhardwaj, and M Pope, and M K Louder, and P K Ehrenberg, and P W Parren, and D R Burton, and H Katinger, and T C VanCott, and M L Robb, and D L Birx, and J R Mascola
July 1992, Science (New York, N.Y.),
S S Frankel, and R M Steinman, and N L Michael, and S R Kim, and N Bhardwaj, and M Pope, and M K Louder, and P K Ehrenberg, and P W Parren, and D R Burton, and H Katinger, and T C VanCott, and M L Robb, and D L Birx, and J R Mascola
November 1992, The Journal of investigative dermatology,
S S Frankel, and R M Steinman, and N L Michael, and S R Kim, and N Bhardwaj, and M Pope, and M K Louder, and P K Ehrenberg, and P W Parren, and D R Burton, and H Katinger, and T C VanCott, and M L Robb, and D L Birx, and J R Mascola
July 1993, The Journal of infectious diseases,
S S Frankel, and R M Steinman, and N L Michael, and S R Kim, and N Bhardwaj, and M Pope, and M K Louder, and P K Ehrenberg, and P W Parren, and D R Burton, and H Katinger, and T C VanCott, and M L Robb, and D L Birx, and J R Mascola
August 1997, Journal of virology,
Copied contents to your clipboard!